Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer (NCT04502602)

🧪 Interventions in This Study

• Neratinib 160 mg (DRUG)
• Neratinib 200 mg (DRUG)
• Neratinib 240 mg (DRUG)
• Niraparib 100 mg (DRUG)
• Niraparib 200 mg (DRUG)
• Niraparib 300 mg (DRUG)
• Niraparib at RP2D (DRUG)
• Neratinib at RP2D (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Virginia Commonwealth University — Richmond, Virginia

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Solid Tumor

• Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
• A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
• QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
• A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
• First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
• A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas

Explore by condition: All Advanced Solid Tumor clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.